No Cover Image

Journal article 1032 views 308 downloads

The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe

Natalie Bohm, Sarah Bermingham, Frank Grimsey Jones, Daniela C. Gonçalves-Bradley, Alex Diamantopoulos, Jessica R. Burton, Hamish Laing Orcid Logo

PharmacoEconomics, Volume: 40, Issue: 1, Pages: 13 - 29

Swansea University Author: Hamish Laing Orcid Logo

  • 57416.pdf

    PDF | Version of Record

    © The Author(s) 2021. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

    Download (770.81KB)

Check full text

DOI (Published version): 10.1007/s40273-021-01070-1

Abstract

Objectives To outline the challenges of implementing Outcomes-Based Contracts (OBCs) in Europe. Methods A scoping review was conducted, building on the searches of a previous systematic review and updating them for December 2017 until May 2021. The combined results were screened, based on inclusion...

Full description

Published in: PharmacoEconomics
ISSN: 1170-7690 1179-2027
Published: Springer Science and Business Media LLC 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa57416
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2021-09-07T13:38:27Z
last_indexed 2022-01-18T04:25:40Z
id cronfa57416
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-01-17T13:31:16.5467358</datestamp><bib-version>v2</bib-version><id>57416</id><entry>2021-07-19</entry><title>The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe</title><swanseaauthors><author><sid>be60df55bc8e44cf2aacf7230876588d</sid><ORCID>0000-0002-5661-7937</ORCID><firstname>Hamish</firstname><surname>Laing</surname><name>Hamish Laing</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-07-19</date><deptcode>BBU</deptcode><abstract>Objectives To outline the challenges of implementing Outcomes-Based Contracts (OBCs) in Europe. Methods A scoping review was conducted, building on the searches of a previous systematic review and updating them for December 2017 until May 2021. The combined results were screened, based on inclusion and exclusion criteria. All identified studies published in the English language that described specific OBC schemes for medicines in European countries were included. Insights into the challenges of OBC were extracted and analysed to develop a conceptual framework. Results Ten articles from the previous systematic review matched our inclusion criteria, along with fourteen articles from electronic searches. Analysis of these 24 articles and classification of the challenges revealed that there are multiple barriers which must be overcome if OBCs that benefit all stakeholders are going to be adopted widely across Europe. These challenges were grouped according to five key themes: negotiation framework; outcomes; data; administration and implementation; and laws and regulation.Conclusions If the promise of OBCs is to be fully realised in Europe, there remain major challenges that need to be overcome by all stakeholders working in partnership. The overlapping and interconnected nature of these challenges highlights the complexity of OBC arrangements</abstract><type>Journal Article</type><journal>PharmacoEconomics</journal><volume>40</volume><journalNumber>1</journalNumber><paginationStart>13</paginationStart><paginationEnd>29</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1170-7690</issnPrint><issnElectronic>1179-2027</issnElectronic><keywords/><publishedDay>1</publishedDay><publishedMonth>1</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-01-01</publishedDate><doi>10.1007/s40273-021-01070-1</doi><url/><notes/><college>COLLEGE NANME</college><department>Business</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BBU</DepartmentCode><institution>Swansea University</institution><apcterm>External research funder(s) paid the OA fee (includes OA grants disbursed by the Library)</apcterm><funders>Pfizer Ltd.</funders><lastEdited>2022-01-17T13:31:16.5467358</lastEdited><Created>2021-07-19T09:09:19.9864418</Created><path><level id="1">Faculty of Humanities and Social Sciences</level><level id="2">School of Management - Business Management</level></path><authors><author><firstname>Natalie</firstname><surname>Bohm</surname><order>1</order></author><author><firstname>Sarah</firstname><surname>Bermingham</surname><order>2</order></author><author><firstname>Frank Grimsey</firstname><surname>Jones</surname><order>3</order></author><author><firstname>Daniela C.</firstname><surname>Gon&#xE7;alves-Bradley</surname><order>4</order></author><author><firstname>Alex</firstname><surname>Diamantopoulos</surname><order>5</order></author><author><firstname>Jessica R.</firstname><surname>Burton</surname><order>6</order></author><author><firstname>Hamish</firstname><surname>Laing</surname><orcid>0000-0002-5661-7937</orcid><order>7</order></author></authors><documents><document><filename>57416__21012__9d04fc4a15e946dfa74058e2f211cb11.pdf</filename><originalFilename>57416.pdf</originalFilename><uploaded>2021-09-27T12:22:05.4885419</uploaded><type>Output</type><contentLength>789305</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; The Author(s) 2021. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-01-17T13:31:16.5467358 v2 57416 2021-07-19 The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe be60df55bc8e44cf2aacf7230876588d 0000-0002-5661-7937 Hamish Laing Hamish Laing true false 2021-07-19 BBU Objectives To outline the challenges of implementing Outcomes-Based Contracts (OBCs) in Europe. Methods A scoping review was conducted, building on the searches of a previous systematic review and updating them for December 2017 until May 2021. The combined results were screened, based on inclusion and exclusion criteria. All identified studies published in the English language that described specific OBC schemes for medicines in European countries were included. Insights into the challenges of OBC were extracted and analysed to develop a conceptual framework. Results Ten articles from the previous systematic review matched our inclusion criteria, along with fourteen articles from electronic searches. Analysis of these 24 articles and classification of the challenges revealed that there are multiple barriers which must be overcome if OBCs that benefit all stakeholders are going to be adopted widely across Europe. These challenges were grouped according to five key themes: negotiation framework; outcomes; data; administration and implementation; and laws and regulation.Conclusions If the promise of OBCs is to be fully realised in Europe, there remain major challenges that need to be overcome by all stakeholders working in partnership. The overlapping and interconnected nature of these challenges highlights the complexity of OBC arrangements Journal Article PharmacoEconomics 40 1 13 29 Springer Science and Business Media LLC 1170-7690 1179-2027 1 1 2022 2022-01-01 10.1007/s40273-021-01070-1 COLLEGE NANME Business COLLEGE CODE BBU Swansea University External research funder(s) paid the OA fee (includes OA grants disbursed by the Library) Pfizer Ltd. 2022-01-17T13:31:16.5467358 2021-07-19T09:09:19.9864418 Faculty of Humanities and Social Sciences School of Management - Business Management Natalie Bohm 1 Sarah Bermingham 2 Frank Grimsey Jones 3 Daniela C. Gonçalves-Bradley 4 Alex Diamantopoulos 5 Jessica R. Burton 6 Hamish Laing 0000-0002-5661-7937 7 57416__21012__9d04fc4a15e946dfa74058e2f211cb11.pdf 57416.pdf 2021-09-27T12:22:05.4885419 Output 789305 application/pdf Version of Record true © The Author(s) 2021. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License true eng http://creativecommons.org/licenses/by-nc/4.0/
title The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
spellingShingle The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
Hamish Laing
title_short The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
title_full The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
title_fullStr The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
title_full_unstemmed The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
title_sort The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
author_id_str_mv be60df55bc8e44cf2aacf7230876588d
author_id_fullname_str_mv be60df55bc8e44cf2aacf7230876588d_***_Hamish Laing
author Hamish Laing
author2 Natalie Bohm
Sarah Bermingham
Frank Grimsey Jones
Daniela C. Gonçalves-Bradley
Alex Diamantopoulos
Jessica R. Burton
Hamish Laing
format Journal article
container_title PharmacoEconomics
container_volume 40
container_issue 1
container_start_page 13
publishDate 2022
institution Swansea University
issn 1170-7690
1179-2027
doi_str_mv 10.1007/s40273-021-01070-1
publisher Springer Science and Business Media LLC
college_str Faculty of Humanities and Social Sciences
hierarchytype
hierarchy_top_id facultyofhumanitiesandsocialsciences
hierarchy_top_title Faculty of Humanities and Social Sciences
hierarchy_parent_id facultyofhumanitiesandsocialsciences
hierarchy_parent_title Faculty of Humanities and Social Sciences
department_str School of Management - Business Management{{{_:::_}}}Faculty of Humanities and Social Sciences{{{_:::_}}}School of Management - Business Management
document_store_str 1
active_str 0
description Objectives To outline the challenges of implementing Outcomes-Based Contracts (OBCs) in Europe. Methods A scoping review was conducted, building on the searches of a previous systematic review and updating them for December 2017 until May 2021. The combined results were screened, based on inclusion and exclusion criteria. All identified studies published in the English language that described specific OBC schemes for medicines in European countries were included. Insights into the challenges of OBC were extracted and analysed to develop a conceptual framework. Results Ten articles from the previous systematic review matched our inclusion criteria, along with fourteen articles from electronic searches. Analysis of these 24 articles and classification of the challenges revealed that there are multiple barriers which must be overcome if OBCs that benefit all stakeholders are going to be adopted widely across Europe. These challenges were grouped according to five key themes: negotiation framework; outcomes; data; administration and implementation; and laws and regulation.Conclusions If the promise of OBCs is to be fully realised in Europe, there remain major challenges that need to be overcome by all stakeholders working in partnership. The overlapping and interconnected nature of these challenges highlights the complexity of OBC arrangements
published_date 2022-01-01T04:13:08Z
_version_ 1763753893681954816
score 11.037056

Similar Items